Congenital Adrenal Hyperplasia Clinical Trial
Official title:
The Prevalence Of Gonadal Changes In Patients With Congenital Adrenal Hyperplasia
To detect the prevalence of gonadal changes by US among the patients with CAH. - assess the patients' radiological findings in relation to their hormonal profile. - early management and prevention of complications resulting from possible gonadal dysfunction.
Several factors contribute to the impaired fertility in CAH patients, such as androgen excess, adrenal progesterone hypersecretion and adrenal rest tumours (ARTs). ARTs are derived from ectopic adrenal cells that migrated to the gonads in foetal life, and their growth is under control of adrenocorticotropic hormone (ACTH) and angiotensin II . The common cause of infertility in males with CAH is testicular adrenal rest tumours (TARTs) , which have been well documented in CAH male patients, with an incidence up to 94%. They could be easily imaged by US and MRI studies. TARTs are associated with the risk of seminal duct obstruction, leading to azoospermia and permanent damage of the surrounding testicular tissue. TARTs can present as single nodules , and as multiple nodules in 16% of patients. Increasing the dosage of hormone therapy can cause early TARTs lesions to shrink or completely resolve, while advanced lesions may require surgical removal . High prevalence of impaired fertility is not restricted to men; as it was reported also in women with CAH. Androgen excess is usually implicated in girls and women with CAH for whom medical treatment is unavailable or who are noncompliant with their therapy . Adrenal androgens act either directly or through the dysfunction caused at the hypothalamic pituitary axis. Interestingly, ovarian hyperandrogenism could occur even when CAH is well controlled on glucocorticoid therapy . Females with CAH may become infertile for several reasons, such as chronic anovulation, which was demonstrated in up to 50% of the patients with non-classic CAH . Bilateral enlarged ovaries, bilateral ovarian cysts, and ovarian adrenal rest tumour (OART) may also occur and can be detected by US. OART impairs ovarian function in CAH females by displacing normal ovarian tissue and by locally producing steroids, which interfere with normal ovarian function. It should be considered when ovarian masses are detected. If detected early enough and glucocorticoid therapy is received, it is possible that it will decrease in size following suppression of ACTH levels. Polycystic ovary syndrome (PCOS) is another common condition associated with hyperandrogenism. The prevalence of PCOS is increased in women with both classical and non-classical CAH. The association of CAH with ultrasonically detected PCOS was confirmed in 83%, 40% and 3% of the adult patients, postpubertal girls and pre and peripubertal girls respectively . Under treatment of ARTs, PCOS and other gonadal comorbidities negatively influences the quality of life as well as sexual outcomes in patients with CAH. Besides, recognizing these conditions and identifying characteristic US features of gonadal dysfunction is important, so as to avoid misdiagnosing them as malignancies, which can lead to unnecessary interventions. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03687242 -
Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
|
Phase 2 | |
Active, not recruiting |
NCT04544410 -
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
|
Phase 2 | |
Not yet recruiting |
NCT04087148 -
Linear Growth of Children With Congenital Adrenal Hyperplasia
|
||
Completed |
NCT03162159 -
Adult Height Prediction in Congenital Adrenal Hyperplasia
|
||
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Enrolling by invitation |
NCT05162950 -
Effects and Importance of Epinephrine/Adrenalin Deficiency in CAH
|
||
Withdrawn |
NCT03532022 -
Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy
|
Phase 3 | |
Recruiting |
NCT02795871 -
Prenatal Dex Study
|
N/A | |
Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|
||
Not yet recruiting |
NCT04536662 -
Comparisons of Different Forms of Glucocorticoid on the Recovery of Reproductive Function in Patients With 21α-hydroxylase Deficiency
|
Phase 4 | |
Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
Active, not recruiting |
NCT04490915 -
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
|
Phase 3 | |
Completed |
NCT01807364 -
Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia
|
N/A | |
Completed |
NCT02804178 -
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
|
Phase 2 | |
Completed |
NCT03019614 -
An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone
|
Phase 1 | |
Not yet recruiting |
NCT04293133 -
Final Height in Patients With CAH
|
||
Recruiting |
NCT03897504 -
Surgical Evaluation of Using the Prepuce in Feminizing Genitoplasty
|
N/A | |
Recruiting |
NCT05663320 -
A Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adults With Congenital Adrenal Hyperplasia
|
N/A | |
Active, not recruiting |
NCT04806451 -
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
|
Phase 3 | |
Completed |
NCT01875640 -
Decision Support for Parents Receiving Information About Child's Rare Disease
|